Drugs / PLD 30 mg/m2, i.v.,d1; once every 21days
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT03794778 | Mar 2019 → Mar 2024 | — | Women's Hospital School Of Medicine Zhejiang University | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PLD 30 mg/m2, i.v.,d1; once every 21days | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03794778 ↗ |
| Known as | PLD | “To compare the efficacy and safety of pegylated liposomal doxorubicin (PLD) plus carboplatin versus paclitaxel plus carboplatin as first-line treatment in patients with...” PMID 41709925 ↗ Feb 2026 |